Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Money raised by industrial, drug funds
by Michael McCoy
October 24, 2016
| A version of this story appeared in
Volume 94, Issue 42
Arsenal Capital Partners has raised $1.3 billion for its fourth investment fund. The New York City-based private equity firm invests in lower middle-market specialty industrial and health care companies. Current investments include the radiation cure resins maker IGM Resins and the drug development software firm Certara. Meanwhile, Sofinnova Partners has raised $650 million for its latest biotech investment fund. The fund plans to invest between $15 million and $35 million in 20 to 25 companies. Sofinovva says it has invested in 46 drug companies since 2007.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X